NICE approves idelalisib (Zydelig®) for the tr... - CLL Support
NICE approves idelalisib (Zydelig®) for the treatment of chronic lymphocytic leukaemia in England and Wales
You need to be a member of this community to see this post.
Read more about...
16 Replies
You need to be a member of this community to see hidden responses.
Not what you're looking for?
You may also like...
UK NICE Approves Ibrutinib +Venetoclax for First Line treatment for ALL Patients from today
Probably one of the best news stories that we have been able to announce in many years for patients...
NICE publish guidance to enable NHS England commissioning of Venetoclax for treating CLL; within CDF managed access agreement.
Today The National Institute for Health and Care Excellence (NICE) have published technology...
CLLSA and Leukaemia Care Joint Response to NHS England regarding Ibrutinib Prescribing as per NICE TA
This is the letter sent to Professor Peter Clarke on 2nd July 2018 for the review of Ibrutinib...
Growth dynamics in naturally progressing chronic lymphocytic leukaemia
Abstract from Nature, 29/5/19 - Unfortunately the whole article is behind a paywall.
"We used...
Leukaemia Care Updated Patient Information - Richter's Syndrome in Chronic Lymphocytic Leukaemia
Leukaemia Care is a UK charity so the support information is UK based. However the information...
Related Posts
- Interesting recently published overview of Chronic Lymphocytic Leukaemia and Hairy-Cell Leukaemia
FDA Approves Zanubrutinib for Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphom
Health Canada approves Ibrutinib plus Rituximab for First Line Treatment of Patients with Chronic Lymphocytic Leukemia (CLL)- CLLSA Response to NHS England Failing to Fund Ibrutinib in line with NICE Guidance
- Chronic Lymphocytic Leukaemia: "an overview" & A look at the future of CLL treatment: "New treatment options". Dr George Follows - June 2014
